Histopatologická diagnostika kožních melanocytárních lézí

Histopathology of skin melanocytic lesions

Melanocytic lesions are instable tumors, the genome of which and its changes determinate their morphology and biological properties. Intermediate lesions share histomorphological features of both, nevi and melanoma. Melanocytomas represent a group of them separated on the basis of recent molecular-biological studies. The article summarizes benign, intermediate, malignant and combined melanocytic skin lesions and offers practical recommendations for diagnosis.

Keywords:

classification – histopathology – melanocytic lesions – genetic alterations – dermoscopy-histopathology correlations – intermediate lesions – melanocytomas – practical recommendations for diagnosis

Autoři: Lumír Pock; Alena Skálová
Vyšlo v časopise: Čes.-slov. Patol., 60, 2024, No. 1, p. 12-34
Kategorie: Přehledový článek

Souhrn

Melanocytární léze jsou nestabilní tumory, jejichž genom a změny v něm determinují jejich morfologii a biologické vlastnosti. Mezi névy a melanomy jsou v různém smyslu atypické, intermediální léze. Na základě nových molekulárně-biologických poznatků bylo možné v jejich rámci vyčlenit tzv. melanocytomy. Článek poskytuje aktuální souhrn benigních, intermediálních, maligních a kombinovaných melanocytárních kožních lézí a nabízí praktická doporučení při jejich diagnostice.

Klíčová slova:

klasifikace – histopatologie – melanocytární léze – genetické alterace – dermatoskopicko-histopatologické korelace – melanocytomy – praktická diagnostická doporučení – léze intermediální

Stránka z

Zdroje

Ackley CD, Prieto VG, Bentley RC, Horenstein MG, Seigler HF, Shea CR. Primary chondroid melanoma. J Cutan Pathol 2001; 28: 482-485.
Elder DE, Barnhill RL, Bastian BC et al. Melanocytic neoplasms. In: WHO Classification of Tumours Editorial Board.: Skin Tumours. (Internet: beta version ahead of print. Lyon(France): International Agency for Research on Cancer; 2023. (WHO classification of tumours series, 5th ed.; vol. 12). Availalable from: https://tumourclassification.iarc.who.int/chapters/64
Urso C. Melanocytic skin neoplasms: what lesson from genomic aberrations? Am J Dermatopathol 2019; 4(9): 623-629.
Cohen JN, Yeh I, Mully TW, LeBoit PE, McCalmont TH. Genomic and clinicopathologic characteristics of PRKAR1 A-inactivated melanomas. J Surg Pathol 2020; 44(6): 805-816.
Andea AA. Molecular testing for melanocytic tumors: a practical update. Histopathology; 2022, 80: 150-165.
Tsao H, Bevona C, Goggins W, et al. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population based estimate. Arch Dermatol 2003; 139(3):282-288.
Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA. The 2018 World health organization classification of cutaneous, mucosal, and uveal melanoma. Arch Pathol Lab Med 2022; 144(4): 500-522.
Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373,(20): 1926-1936.
Busam Klaus, J. Pathology of Melanocytic Tumors. Available from: Elsevier eBooks+, Elsevier OHCE, 2018.
Massi G, LeBoit PE. Histological diagnosis of nevi and melanoma (2nd ed.). Heidelberg, Springer; 2014: 752 p.
Yeh I, Busam KJ. Spitz melanocytic tumours – a review. Histopathology 2022; 80: 122-134.
McKee PH. Clues to the diagnosis of atypical melanocytic lesions. Histopathology 2010; 56(1): 100-111.
Elmore JG, Barnhill RL, Elder DE et al. Pathologist´s diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ 2017; 28(6): 357.
Lodha S, Daggar S, Celebi JT, et al. Discordance in the diagnosis of difficult melanocytic neoplasms in the clinical settings. J Cutan Pathol. 2008; 35(4): 349-352.
Cerroni L, Barnhill RL, Elder D, et al. Melanocytic tumors of uncertain malignant potential. Results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008. Am Surg Pathol 2010; 34: 314-326.
Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997; 277(18): 1439-1444.
Ebbelaar CF, Schrader AM, van Dijk M, et al. Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing. Mod Pathol 2022; 35(8): 1110-1120.
Zembowicz A, Carney JA, Mihm MC. Pigmented epithelioid melanocytoma: a lowgrade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol 2004; 28(1): 31-40.
Donatti M, Martinek P, Steiner P et al. Novel insight into the BAP1-inactivated melanocytic tumor. Mod Pathol 2022; 35: 664-675.
Quan VL., Panah E., Zhang B., et al. The role of gene fusions in melanocytic neoplasms. J Cutan Pathol 2019; 46 (11): 878-887.
Motaparthi K, Kim J, Andea AA, et al. TERT and TERT promoter in melanocytic neoplasms: Current concepts in pathogenesis, diagnosis, and prognosis. J Cutan Pathol 2020; 47 (8): 710-719.
Lallas A, Kyrgidis A, Ferrara G, et al. Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. Lancet Onco, 2014; 15(4): 178-183.
Pock L. Lentiga a melanocytární névy. In: Pock L, Fikrle T, Drlík L, Zloský P. Dermatoskopický atlas. 2. vyd., Praha: Phlebomedica, 2008: 34-76. ISBN 978-80-901298-5-6.
Pock L, Trnka J, Vosmík F, Záruba F. Systematized Progradient Multiple Combined Melanocytic and Blue Nevus. Am J Dermatopatol 1991; 13(3): 282-287.
Varey AHR, Williams GJ, Lo SN, et al. Clinical management of melanocytic tumours of uncertain malignant potential (MelTUMPs), including melanocytomas: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2023; 37(5): 859-870.
Vermariën-wang J, Doeleman T, van Doorn R, et al. Ambiguous melanocytic lesions: A retrospective cohort study of incidence and outcome of melanocytic tumor of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferation of uncertain significance (SAMPUS) in the Netherlands. J Am Acad Dermatol 2023; 88(3): 602-608.
de la Fouchardiere A, Blokx W, van Kempen, LC, et al. ESP, EORTC, AND EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. Virchows Arch 2021; 479(1): 3-11.
Marsden JR, Newton-Bishop JA, Burrows l, et al.: Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Derm 2010; 163: 238-256.
Maurici A, Miceli R, Patuzzo R., et al. Analysis of sentinel node biopsy and clinicopathologic features as prognostic factors in patients with atypical melanocytic tumors. J Natl Compr Canc Netw 2020; 18(10): 1327-1336.
Hosler G.A., Murphy K.M.: Ancillary testing for melanoma: current trends and practical considerations. Human Pathology, ttps://doi. org/10.1016/j.humpatj.2023.05.002. Available online 11 May 2023. In Press.
Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME Expression in Melanocytic Tumors. Am J Surg Pathol 2018; 42: 1456-1465.
Cesinaro AM, Gallo G, Manfredini S, Maiorana A, Bettelli SR. ROS1 pattern of immunostaining in 11 cases of spitzoid tumour: comparison with histopathological, fluorescence in-situ hybridisation and next-generation sequencing analysis. Histopathology 2021; 79, 966-974.
Alomari AK, Miedema JR, Carter MD et al. DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach. Mod Pathol 2020; 33: 1307-1317.